⚠ Evidence warning: Clinical trials or other evidence do not support the claim that surgery at an earlier stage of epiretinal membrane gives better vision afterward, which is put forward as an argument against waiting. This page keeps it as a report of what people, websites or other media say.

Epiretinal Membrane

Epiretinal Membrane — scientific infographic poster

Epiretinal membrane (ERM) — also called macular pucker, cellophane maculopathy, or premacular fibrosis — is a thin fibrocellular layer that grows on the inner surface of the retina over the macula. It is common in adults over 60, often discovered incidentally, and ranges from a minor finding requiring only monitoring to a treatable cause of significant visual distortion. Surgical outcomes are excellent when intervention is timely.

  1. Epiretinal Membrane Explained
  2. Pathophysiology
  3. Symptoms and Natural History
  4. Diagnosis
  5. Grading and Classification
  6. Surgical Treatment — Vitrectomy + Membrane Peeling
  7. Prognosis and Outcomes
  8. Non-Surgical Management and Monitoring
  9. Nutrition and Eye Health Support
  10. Cautions and Considerations
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Epiretinal Membrane Explained

An epiretinal membrane is a thin, translucent-to-opaque sheet of fibrocellular tissue that develops on the inner surface of the retina, predominantly over the macula — the central, high-resolution region of the retina responsible for reading, face recognition, and fine detail. As the membrane contracts, it distorts the underlying retinal architecture, producing the visual distortion and blur that characterize the condition.

ERM goes by several names depending on how it is described:

Prevalence

In the Blue Mountains Eye Study of 3,654 Australians aged 49 or older, ERM was found in 7% overall: in 1.9% of people under 60, 7.2% at 60–69, 11.6% at 70–79 and 9.3% at 80 and older, with slightly higher rates in women. It was present in both eyes in 31% of those affected. The same study found ERM in 16.8% of people who had had cataract surgery in one or both eyes and in 16.1% of people with a blocked retinal vein (retinal vein occlusion), and the later, scarred form with retinal folds (preretinal macular fibrosis) was linked to diabetes (odds ratio 3.2) even in people without diabetic eye disease. Most are asymptomatic discoveries on routine retinal examination or during evaluation for another ocular complaint.

Primary vs Secondary ERM

Back to Table of Contents

Pathophysiology

The formation of an epiretinal membrane follows a reproducible cellular cascade, most commonly initiated by posterior vitreous detachment.

Step 1: Posterior Vitreous Detachment (PVD)

The vitreous humor — a gel filling the eye's central cavity — is attached to the retina at birth. With age, it undergoes syneresis (liquefaction) and progressively separates from the retinal surface. When separation occurs near the macula, microscopic breaks in the inner limiting membrane (ILM) allow retinal glial cells, retinal pigment epithelium (RPE) cells, hyalocytes (vitreous resident cells), fibrous astrocytes, and macrophages to migrate onto the retinal surface. PVD is therefore the essential initiating event in most idiopathic ERM.

Step 2: Cell Migration and Proliferation

The migrating cells settle on the inner limiting membrane and begin to proliferate. The cellular composition of the resulting membrane includes:

Step 3: Membrane Formation and Contraction

Cells lay down extracellular matrix proteins — collagen types I, II, and IV, fibronectin, laminin — forming a fibrocellular membrane. Critically, myofibroblasts within the membrane generate centripetal contractile forces. This pulls the underlying retina into folds and wrinkles, distorting the architecture of the macula and the geometry of the foveal pit (the depression at the macula's center responsible for 20/20 vision).

Resulting Visual Dysfunction

The mechanical distortion of the macula produces the characteristic symptoms: metamorphopsia (straight lines appear wavy), micropsia (objects appear smaller than normal), and reduced visual acuity from displacement of the photoreceptors from their optimal focal position. Unlike age-related macular degeneration, ERM does not destroy photoreceptors — the visual cells remain intact beneath the membrane, which is why surgical peeling can achieve substantial visual recovery even years after symptom onset.

Back to Table of Contents

Symptoms and Natural History

Common Symptoms

Asymptomatic Cases

A significant proportion of ERM — particularly early or thin membranes (cellophane maculopathy stage) — cause no visual symptoms and are found only during routine dilated fundus examination or OCT imaging performed for other reasons. These require monitoring rather than intervention.

Natural History

ERM does not follow a uniform course:

Progression Risk Factors

Back to Table of Contents

Diagnosis

Optical Coherence Tomography (OCT) — Gold Standard

OCT provides cross-sectional imaging of the retina at micron-level resolution and is the cornerstone of ERM diagnosis and monitoring. Key OCT findings include:

Visual Acuity Testing

Standard Snellen chart testing quantifies vision loss. In early ERM, acuity may be 20/25 to 20/30. In moderate disease, 20/40 to 20/60. In severe ERM, 20/100 or worse. The threshold of 20/40 or worse with functional impact is commonly used to guide the decision to offer surgery.

Amsler Grid

A simple grid of horizontal and vertical lines viewed at reading distance with one eye covered. Distortion or waviness of the lines (metamorphopsia), missing areas, or blurring indicate macular disease. Cheap, reproducible, and excellent for both clinical screening and home monitoring between appointments. Best performed with reading glasses or appropriate near correction in good lighting.

Fluorescein Angiography (FA)

Intravenous dye study that illuminates retinal blood vessels and identifies areas of leakage, ischemia, or neovascularization. Used in ERM primarily to exclude other causes of central visual distortion — macular degeneration (wet form), diabetic macular edema, or retinal vein occlusion. Not required in straightforward idiopathic ERM.

Microperimetry

Maps the sensitivity of individual macular locations under direct retinal imaging, correlating functional loss with structural OCT findings. Used in research settings and for detailed preoperative and postoperative evaluation in complex cases.

OCT Angiography (OCTA)

Non-invasive imaging of the retinal vasculature, including assessment of the foveal avascular zone (FAZ). In ERM, the FAZ may be distorted or enlarged, correlating with visual outcome. Increasingly used alongside standard OCT.

Back to Table of Contents

Grading and Classification

OCT-Based Govetto Grading System

This staging scheme, published in 2017 by Govetto and colleagues from the OCT scans of 194 eyes, grades ERM by its OCT appearance:

In the study, EIFL appeared in 63 of the 194 eyes (32.5%) and went with significantly lower vision, and vision declined step by step from Stage 1 through Stage 4. The authors suggest the stage may influence visual prognosis. Studies differ on surgical timing: a 1999 study reported that results of surgery worsen the longer symptoms have lasted, while a 2022 study of 413 people with mild idiopathic ERM found that deferring surgery until it was needed did not lead to worse final vision than operating at once (see Natural History). Earlier stage at surgery is associated with better postoperative visual outcomes — a key argument for not waiting until advanced disease before offering surgery to motivated patients.

Gass Classification (Historical)

Described by J. Donald Gass based on biomicroscopic (slit-lamp) findings:

OCT has largely replaced purely biomicroscopic grading in current clinical practice.

Back to Table of Contents

Surgical Treatment — Vitrectomy + Membrane Peeling

Surgical Indications

Surgery is usually considered when:

Pars Plana Vitrectomy (PPV)

The standard surgical approach. Three tiny (23-, 25-, or 27-gauge) instrument ports are placed through the pars plana (the non-visual peripheral retina), avoiding the lens and retina. The vitreous gel is removed using a high-speed vitreous cutter, creating access to the retinal surface. Modern small-gauge (25g/27g) vitrectomy is sutureless, performed under local anesthesia with sedation, and takes 30–60 minutes.

ERM Peeling

The epiretinal membrane is grasped with microsurgical intraocular forceps and peeled off the retinal surface under high magnification. A key challenge is identifying the membrane's edge — surgeons use vital dyes to stain the membrane and improve visualization:

Internal Limiting Membrane (ILM) Peeling

After ERM peeling, many surgeons perform concurrent ILM peeling — removing the thin basement membrane that sits between the retina and the vitreous cavity. Rationale: the ILM can serve as a scaffold for residual or new membrane cells to repopulate, driving ERM recurrence. A 2024 review that pooled 19 studies (1,291 eyes) found that peeling the ILM as well gave the same final vision as leaving it (p = 0.68), but about a quarter of the risk of the membrane growing back (risk ratio 0.26) and fewer repeat operations (risk ratio 0.17); the authors rate the certainty of this evidence as moderate, with possible bias because most of the studies were not randomised. The trade-off is a slightly higher rate of microperimetry-detected paracentral sensitivity deficits — representing subclinical Müller cell disruption — though most patients do not notice this clinically.

Cataract Formation After Vitrectomy

Nuclear sclerotic cataract (lens clouding) develops in nearly all phakic (natural-lens) patients after vitrectomy, typically within 1–2 years. Options:

Surgical Outcomes

Back to Table of Contents

Prognosis and Outcomes

Visual Acuity Recovery

Most studies report mean postoperative visual acuity improvement of 2–3 Snellen lines at 1 year. Approximately 80–90% of operated eyes show some improvement; fewer than 5% worsen. The best predictor of postoperative VA is preoperative VA — patients with better vision at surgery tend to achieve better vision afterward, reinforcing the argument for earlier rather than later intervention once symptoms are functionally limiting. In a 2022 study of 413 people with mild idiopathic ERM, however, the minority whose surgery was deferred until they progressed ended with final vision similar to those operated on immediately.

Metamorphopsia Recovery

Distortion recovers more slowly than VA and is less predictable. At 6 months, 60–70% of patients report improved metamorphopsia. Most continued improvement occurs up to 24 months. Some degree of residual distortion persists in 20–30% of patients even after successful ERM removal, reflecting structural changes to the photoreceptor layer that persist after the membrane is peeled.

Factors Predicting Better Outcomes

Recurrence

In the 2024 pooled analysis of 19 studies, the membrane grew back less often when the ILM was also peeled (risk ratio 0.26), and repeat surgery was needed less often (risk ratio 0.17). In Michels' 1981 series of 50 operated eyes, sizable amounts of membrane tissue grew back in two eyes. Recurrent ERM is typically less aggressive than the original and often managed conservatively.

Fellow Eye Risk

10–20% of patients with unilateral ERM will develop ERM in the fellow eye over follow-up periods of 5 years or more. Annual dilated fundus examination with OCT of the fellow eye is the usual follow-up after a diagnosis of unilateral ERM.

Back to Table of Contents

Non-Surgical Management and Monitoring

Watchful Waiting

For patients with mild, stable, asymptomatic ERM — particularly cellophane maculopathy (Govetto Stage 1) without distortion — observation is the usual initial approach. Many such membranes remain stable for years. Surgery carries real risks and a recovery period; it is elective and is usually deferred when the condition is not affecting quality of life.

Serial OCT Monitoring

For patients under observation, OCT imaging every 6–12 months tracks membrane thickness, retinal thickening, and foveal contour. Any progression — worsening OCT morphology, new symptoms, or declining VA — prompts re-discussion of surgical timing.

Home Amsler Grid Monitoring

Daily Amsler grid testing at home is the usual home check (with reading glasses or correct near correction, in good lighting, one eye covered at a time). New distortion, missing areas, or a change in the appearance of the grid are signs eye clinics treat as reasons for a prompt examination rather than waiting for the next scheduled appointment.

Anti-VEGF Injections

Intravitreal anti-VEGF agents (bevacizumab, ranibizumab, aflibercept) are the mainstay of treatment for wet age-related macular degeneration and diabetic macular edema. They have no established role in idiopathic ERM, where neovascularization is not part of the pathophysiology. In secondary ERM driven by a vascular condition (diabetic retinopathy, retinal vein occlusion), anti-VEGF treatment of the underlying condition may secondarily reduce membrane stimulus.

No Proven Medical Therapy

As of 2026, no oral medication, eye drop, or dietary supplement has been demonstrated in controlled trials to prevent ERM formation, slow progression, or cause regression. Products sold for ERM have no proven benefit.

Back to Table of Contents

Nutrition and Eye Health Support

No specific diet or supplement has been proven to prevent or treat ERM. However, several nutrients support overall retinal and macular health and are often discussed, particularly when patients have concurrent risk factors such as diabetes, hypertension, or age-related macular degeneration risk.

Omega-3 Fatty Acids

Docosahexaenoic acid (DHA) is a structural component of photoreceptor membranes. Eicosapentaenoic acid (EPA) and docosahexaenoic acid have anti-inflammatory properties relevant to retinal health. Oily fish 2–3 times per week (salmon, sardines, mackerel, herring) or supplements of 1–2 g of combined eicosapentaenoic acid plus docosahexaenoic acid a day are the amounts usually described for retinal health; no trial has specifically studied ERM.

Lutein and Zeaxanthin

These carotenoids are selectively concentrated in the macula, where they function as a blue-light filter and antioxidant. Supplemental lutein 10 mg + zeaxanthin 2 mg daily (or equivalent dietary intake from kale, spinach, cooked eggs) is the amount tested in the Age-Related Eye Disease Study 2 (AREDS2) trial in people with risk factors for age-related macular degeneration; it has not been tested for ERM itself.

AREDS2 Formula

The AREDS2 formula (vitamin C 500 mg, vitamin E 400 international units (IU), zinc 80 mg, copper 2 mg, lutein 10 mg, zeaxanthin 2 mg) reduces progression risk in established intermediate age-related macular degeneration (AMD) by ~25%. For ERM patients who also have age-related macular degeneration risk factors (drusen, family history), the AREDS2 evidence applies. For people with ERM alone, without age-related macular degeneration risk, it is untested for ERM.

Blood Sugar and Blood Pressure Control

Diabetic retinopathy and retinal vein occlusion are common causes of secondary ERM. Tight glycemic control (hemoglobin A1c (HbA1c) target as appropriate for individual patient) and blood pressure management (target <130/80 mmHg in most patients) reduce the risk of the vascular complications that drive secondary ERM formation.

Smoking Cessation

Smoking is the single most modifiable risk factor for age-related macular degeneration and impairs retinal vascular health broadly.

Anti-Inflammatory Diet

A Mediterranean-style diet rich in vegetables, fruit, whole grains, legumes, fish, and olive oil — and low in processed foods, refined carbohydrates, and trans fats — supports vascular and retinal health through anti-inflammatory and antioxidant mechanisms. It has not been tested in ERM itself.

Back to Table of Contents

Cautions and Considerations

Back to Table of Contents

Key Research Papers

Key Research Papers

  1. Mitchell P et al. Prevalence and associations of epiretinal membranes. The Blue Mountains Eye Study, Australia. Ophthalmology. 1997;104(6):1033–1040. — PubMed PMID: 9186446 · doi:10.1016/S0161-6420(97)30190-0
  2. Govetto A et al. Insights into epiretinal membranes: presence of ectopic inner foveal layers and a new optical coherence tomography staging scheme. Am J Ophthalmol. 2017;175:99–113. — PubMed PMID: 27993592 · doi:10.1016/j.ajo.2016.12.006
  3. Michels RG. Vitreous surgery for macular pucker. Am J Ophthalmol. 1981;92(5):628–639. — PubMed PMID: 7304690 · doi:10.1016/s0002-9394(14)74654-9
  4. Haritoglou C et al. Indocyanine green-assisted peeling of the internal limiting membrane in macular hole surgery affects visual outcome: a clinicopathologic correlation. Am J Ophthalmol. 2002;134(6):836–841. — PubMed PMID: 12470751 · doi:10.1016/s0002-9394(02)01816-0
  5. Pournaras CJ et al. Regulation of retinal blood flow in health and disease. Prog Retin Eye Res. 2008;27(3):284–330. — PubMed PMID: 18448380 · doi:10.1016/j.preteyeres.2008.02.002
  6. Koerner F, Garweg J. Vitrectomy for macular pucker and vitreomacular traction syndrome. Doc Ophthalmol. 1999;97(3-4):449–458. — PubMed PMID: 10896363 · doi:10.1023/a:1002412323399
  7. Luu KY et al. Long-term natural history of idiopathic epiretinal membranes with good visual acuity. Eye (Lond). 2019;33(5):714–723. — PubMed PMID: 31000833 · doi:10.1038/s41433-019-0397-z
  8. Al-Khersan H, Shaheen AR, Flynn HW, Smiddy WE. Natural history and surgical timing for idiopathic epiretinal membrane. Ophthalmol Retina. 2022;6(11):978–984. — PubMed PMID: 35272083 · doi:10.1016/j.oret.2022.02.014
  9. Mihalache A et al. Pars plana vitrectomy with or without internal limiting membrane peel for epiretinal membrane: a systematic review and meta-analysis. Ophthalmologica. 2024;247(1):30–43. — PubMed PMID: 37899043 · doi:10.1159/000534851

PubMed Topic Searches

  1. PubMed: Epiretinal membrane vitrectomy outcomes
  2. PubMed: Macular pucker OCT grading
  3. PubMed: ILM peeling ERM recurrence
  4. PubMed: Brilliant blue G vitreoretinal surgery
  5. PubMed: Posterior vitreous detachment ERM
  6. PubMed: Metamorphopsia ERM surgery recovery
  7. PubMed: Ectopic inner foveal layers ERM
  8. PubMed: Lutein zeaxanthin macular health

Back to Table of Contents

Connections

Back to Table of Contents

What Is Epiretinal Membrane?
The Retina Doc — What Is Epiretinal Membrane? A clear patient-focused explanation.
Macular Pucker Explained
BrightFocus Foundation — Macular Pucker Explained: causes, symptoms, and treatment overview.
ERM Surgery: What to Expect
Retina Specialists of Michigan — ERM Surgery: What to Expect before and after vitrectomy.
Vitrectomy for Macular Pucker
American Academy of Ophthalmology — Vitrectomy for Macular Pucker surgical technique overview.
OCT Imaging of Epiretinal Membrane
Moorfields Eye Hospital — OCT Imaging of Epiretinal Membrane: reading the scan findings.
Amsler Grid: How to Use It
Prevent Blindness — Amsler Grid: How to Use It for daily home macular monitoring.
Macular Pucker Patient Story
Wills Eye Hospital — Macular Pucker Patient Story: surgery experience and visual recovery.
When to Have ERM Surgery
Retina Global — When to Have ERM Surgery: timing considerations and patient selection.
ERM vs Macular Degeneration
Cleveland Clinic — ERM vs Macular Degeneration: key differences in diagnosis and treatment.
ILM Peeling in Vitrectomy
Retina Today — ILM Peeling in Vitrectomy: technique, staining dyes, and recurrence prevention.
Visual Recovery After ERM Surgery
Vitreo Retinal Associates — Visual Recovery After ERM Surgery: timeline and what to expect.
Eye Floaters and PVD
Dr. Joseph Allen — Eye Floaters and Posterior Vitreous Detachment: the ERM connection.
Epiretinal Membrane Natural History
Ophthalmic Consultants of Boston — Epiretinal Membrane Natural History: who needs monitoring vs surgery.
Lutein and Eye Health
American Optometric Association — Lutein and Eye Health: macular carotenoids and retinal protection.
Mediterranean Diet for Eye Health
Tufts Nutrition — Mediterranean Diet for Eye Health: omega-3s, carotenoids, and retinal support.
Retina Specialist Q&A
Retina UK — Retina Specialist Q&A: common patient questions about macular conditions answered.